Dicerna doses first patient in phase 1 trial of DCR-PH1 in patients with primary hyperoxaluria type 1
A severe, rare, inherited disorder of the liver, PH1 often results in kidney failure, and there are no approved therapies for the disease. The U.S. Food and Drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.